Methylenetetrahydrofolate reductase (MTHFR) gene 677C>T and 1298A>C polymorphisms are associated with differential apoptosis of leukemic B cells in vitro and disease progression in chronic lymphocytic leukemia

Leukemia

Volumn 18, Issue 11, 2004, Pages 1816-1823

  Nückel, Holger ^a,b   Frey, U H ^a   Durig J ^a   Duhrsen U ^a   Siffert, W ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Apoptosis; Cancer; Chronic lymphocytic leukemia; Folic acid; Genetic polymorphism; MTHFR

Indexed keywords

ADENINE; CYTOSINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THYMINE; TUMOR MARKER;

ADULT; ALLELE; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER GROWTH; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL OBSERVATION; DIFFERENTIAL DIAGNOSIS; EARLY CANCER; ENZYME POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

EID: 8844273358     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403484     Document Type: Article

References (40)

1. Rai KR. Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment. Haematologica 1999; 84 (Suppl. EHA-4): 94-95.
2. Binet JL. Prognostic factors in chronic lymphocytic leukaemia. Haematologica 1999; 84 (Suppl. EHA-4): 96-97.
3. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98: 2633-2639.
4. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
5. Hamblin T. Is chronic lymphocytic leukemia one disease? Haematologica 2002; 87: 1235-1238.
6. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
7. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
8. Durig J, Naschar M, Schmucker U, Renzing-Kohler K, Holter T, Huttmann A et al. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia 2002; 16: 30-35.
9. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
10. Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-2434.
11. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002; 99: 3786-3791.
12. Skibola CF, Smith MT, Kane E, Roman E, Rollinson S, Cartwright RA et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 1999; 96: 12810-12815.
13. Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Sinnett D. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 2003; 103: 252-257.
14. de Franchis R, Sebastio G, Mandato C, Andria G, Mastroiacovo P. Spina bifida, 677T->C mutation, and role of folate. Lancet 1995; 346: 1703.
15. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
16. Botto N, Andreassi MG, Manfredi S, Masetti S, Cocci F, Colombo MG et al. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur J Hum Genet 2003; 11: 671-678.
17. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
18. van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62: 1044-1051.
19. Chen J, Giovannucci E, Kelsey K, Rimm EB, Stampfer MJ, Colditz CA et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4864.
20. Ma J, Stampfer MJ, Giovannucci E, Artigas C, Hunter DJ, Fuchs C et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57 1098-1102.
21. Gerhard DS, Nguyen LT, Zhang ZY, Borecki IB, Coleman BI, Rader JS. A relationship between methylenetetrahydrofolate reductase variants and the development of invasive cervical cancer. Gynecol Oncol 2003; 90: 560-565.
22. Goodman MT, McDuffie K, Hernandez B, Wilkens LR, Bertram CC, Killeen J et al. Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiol Biomarkers Prev 2001; 10: 1275-1280.
23. Song C, Xing D, Tan W, Wei Q, Lin D. Methylenetetrahydrofolate reductase polymorphisms increase risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 2001; 61: 3272-3275.
24. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 1997; 18: 2307-2311.
25. Gao CM, Wu JZ, Liu YT, Ding JH, Li SP, Su P et al. [Interactions between lifestyle, methylanetetrahydrofolate reductase gene and polymorphisms in thymidylate synthase gene with risk of stomach cancer]. Zhonghua Liu Xing Bing Xue Za Zhi 2003; 24: 599-603.
26. Siemianowicz K, Gminski J, Garczorz W, Slabiak N, Goss M, Machalski M et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms in patients with small cell and non-small cell lung cancer. Oncol Rep 2003; 10: 1341-1344.
27. Shen H, Spitz MR, Wang LE, Hong WK, Wei Q. Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 2001; 10 397-401.
28. Semenza JC, Delfino RJ, Ziogas A, Anton-Culver H. Breast cancer risk and methylenetetrahydrofolate reductase polymorphism. Breast Cancer Res Treat 2003; 77: 217-223.
29. Sharp L, Little J, Schofield AC, Pavlidou E, Cotton SC, Miedzybrodzka Z et al. Folate and breast cancer: the role of polymorphisms in methylenetetrahydrofolate reductase (MTHFR). Cancer Lett 2002; 181: 65-71.
30. Durig J, Schmucker U, Duhrsen U. Differential expression of chemokine receptors in B cell malignancies. Leukemia 2001; 15 752-756.
31. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
32. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-526.
33. Ito T, Chiku S, Inoue F, Tomita M, Morisaki T, Morisaki H et al. Estimation of haplotype frequencies, linkage-disequilibrium measures, and combination of haplotype copies in each pool by use of pooled DNA data. Am J Hum Genet 2003; 72: 384-398.
34. Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan DP. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5′-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett 2002; 187: 199-205.
35. Nuckel H, Frey U, Aralh N, Durig J, Duhrsen U, Siffert W. The CC genotype of the C825T polymorphism of the G protein beta3 gene (GNB3) is associated with a high relapse rate in patients with chronic lymphocytic leukaemia. Leuk Lymphoma 2003; 44: 1739-1743.
36. Thunberg U, Tobin G, Johnson A, Soderberg O, Padyukov L, Hultdin M et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet 2002; 360: 1935-1939.
37. Nuckel H, Frey UH, Durig J, Duhrsen U, Siffert W. 1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome. Eur J Haematol 2004; 72: 259-263.
38. Zhang LY, Ibbotson RE, Orchard JA, Gardiner AC, Seear RV, Chase AJ et al. P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. Leukemia 2003; 17: 2097-2100.
39. Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997; 94: 3290-3295.
40. Dianov GL, Timchenko TV, Sinitsina OI, Kuzminov AV, Medvedev OA, Salganik RI. Repair of uracil residues closely spaced on the opposite strands of plasmid DNA results in double-strand break and deletion formation. Mol Gen Genet 1991; 225: 448-452.